Disease · MONDO_0700226
food allergy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. food allergy. Diseases, record MONDO_0700226. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0700226
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Food Hypersensitivity, Food intolerance, allergic disease from food material, allergy of food material, food material allergic disease
- Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LIGELIZUMAB | CHEMBL2109457 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMALIZUMAB | CHEMBL1201589 | Antibody | Phase 2 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| DUPILUMAB | CHEMBL2108675 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| IBRUTINIB | CHEMBL1873475 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OATMEAL, COLLOIDAL | CHEMBL2109173 | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| ABROCITINIB | CHEMBL3655081 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LINVOSELTAMAB | CHEMBL5095373 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IGHE | Immunoglobulin heavy constant epsilon | 2 | Ig epsilon chain C region inhibitor | Phase 3 | https://conductscience.org/library/genes/3497 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| IL4R | Interleukin-4 receptor subunit alpha | 1 | Interleukin-4 receptor subunit alpha antagonist | Phase 2 | https://conductscience.org/library/genes/3566 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 1 | https://conductscience.org/library/genes/3716 | Drugs and targets |
Trials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05678959 | Long-term Extension Study of Ligelizumab in Food Allergy | Phase 3 | 163 | 2025-10-30 | Food Allergy | LIGELIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01157117 | OIT and Xolair® (Omalizumab) in Cow's Milk Allergy | Phase 2 | 77 | 2016-04-06 | Milk Allergy | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02626611 | Multi Immunotherapy to Test Tolerance and Xolair | Phase 2 | 70 | 2017-12-18 | Food Allergy | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03181009 | Multi OIT to Test Immune Markers After Minimum Maintenance Dose | Phase 2 | 60 | 2019-09-20 | Food Allergy | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02643862 | Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients | Phase 1/2 | 48 | 2017-10-25 | Food Allergy | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01750879 | Tolerance Following Peanut Oral Immunotherapy | Phase 1/2 | 41 | 2021-07-28 | Peanut Allergy | OATMEAL, COLLOIDAL | Its record names the disease | ClinicalTrials.gov |
| NCT03149315 | Inhibition of Anaphylaxis by Ibrutinib | Phase 2 | 6 | 2025-01-17 | Food Allergy, Anaphylaxis Food | IBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03679676 | Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) | Phase 2 | 130 | Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy | DUPILUMAB, OMALIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04045301 | Omalizumab to Accelerate a Symptom-driven Multi-food OIT | Phase 2 | 90 | Food IgE-mediated Allergy, Immunotherapy, Omalizumab, Physiological Effects of Drugs | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05069831 | JAK Inhibition in Food Allergy | Phase 1 | 71 | Food Allergy | ABROCITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ligelizumab 120 mg vs Ligelizumab 240 mg: deaths from any cause | 0 of 81 | 0 of 82 | 163 | NCT05678959 | Trial comparisons |
| Ligelizumab 120 mg vs Ligelizumab 240 mg: serious adverse events | 3 of 81 | 2 of 82 | 163 | NCT05678959 | Trial comparisons |
| Group A (300 mg Maintenance Dose) vs Group B (1200 Maintenance Dose): deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT03181009 | Trial comparisons |
| Group A (300 mg Maintenance Dose) vs Group B (1200 Maintenance Dose): serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT03181009 | Trial comparisons |
| Xolair vs Placebo: Desensitization Measured by Proportion of Food Allergic (FA) Participants Who Pass a DBPCFC to 2,000 mg Protein for Each of 2 Allergens at Week 36 | 30 of 36 | 4 of 12 | 48 | NCT02643862 | Trial comparisons |
| Xolair vs Placebo: deaths from any cause | 0 of 36 | 0 of 12 | 48 | NCT02643862 | Trial comparisons |
| Xolair vs Placebo: serious adverse events | 0 of 36 | 0 of 12 | 48 | NCT02643862 | Trial comparisons |
| Peanut Flour vs Placebo (Oat) Flour: Clinical: Safety | 0 of 30 | 0 of 11 | 41 | NCT01750879 | Trial comparisons |
| Peanut Flour vs Oat Flour: deaths from any cause | 0 of 30 | 0 of 11 | 41 | NCT01750879 | Trial comparisons |
| Peanut Flour vs Oat Flour: serious adverse events | 1 of 30 | 0 of 11 | 41 | NCT01750879 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials18
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0700226
GET https://conductscience.org/api/diseases/v1/MONDO_0700226/drugs